ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tadalafil

Also written as “tadalafil”, “Tadalafil 20 mg” and “Cialis Tab. 5mg”.

Its studies are mostly in Erectile Dysfunction · Prostatic Hyperplasia · Hypertension, Pulmonary · Pulmonary Arterial Hypertension · Carcinoma, Non-Small-Cell Lung, led by 8 companies.

Drug pageTadalafil: every studyMany companies study it; this page follows only the 59 they lead. All 193 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 31, 200659 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly490 open or runningphase 4since May 31, 2006Dec 16, 2002none ahead
Chong Kun Dang Pharmaceuticalits history only30 open or runningphase 3since Sep 2, 2015Sep 15, 2014none ahead
Pfizerits history only20 open or runningphase 2since Sep 12, 2005Sep 12, 2005none ahead
Futura Medical Developmentsits history only10 open or runningphase 3since Jul 26, 2021Jul 26, 2021none ahead
Hanmi Pharmaceuticalits history only10 open or runningphase 1since Sep 4, 2014Sep 4, 2014none ahead
Lidia Larrañagaits history only10 open or runningphase 3since May 6, 2020May 6, 2020none ahead
Sanofiits history only10 open or runningphase 3since Jan 17, 2025Jan 17, 2025none ahead
Seattle Gummyits history only11 open or runningphase 1since Feb 17, 2021Feb 17, 2021none ahead

Also a collaborator on its studies: Bristol-Myers Squibb, Gilead Sciences, Nippon Shinyaku and ICOS.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 33 studies since Dec 16, 2002.

  1. May 5, 20102 phase 4 studies in Erectile DysfunctionNCT01122264, NCT01130532
  2. Jun 1, 20102 phase 3 studies in Prostatic HyperplasiaNCT01139762, NCT01152190
  3. Jul 8, 2010Phase 2 study in Erectile DysfunctionNCT01160289 · 410 enrolled · United States
  4. Aug 13, 2010Phase 1 study in Prostatic HyperplasiaNCT01183650 · 24 enrolled · Germany
  5. May 10, 2011Phase 4 study in Erectile DysfunctionNCT01352507 · 383 enrolled · China
  6. Oct 24, 2011Phase 3 study in Prostatic HyperplasiaNCT01460342 · 610 enrolled · Japan, Korea, Republic of
  7. Nov 30, 2011Phase 2 study in Pulmonary Arterial HypertensionNCT01484431 · 20 enrolled · United States, Canada, France and more
  8. Apr 1, 2013Phase 3 study in Hypertension, PulmonaryNCT01824290 · 35 enrolled · United States, Austria, Belgium and more
  9. May 24, 2013Phase 3 study in Muscular Dystrophy, DuchenneNCT01865084 · 331 enrolled · United States, Argentina, Belgium and more
  10. Sep 4, 2013Phase 3 study in Prostatic HyperplasiaNCT01937871 · 909 enrolled · China
  11. Jul 17, 2014Phase 2 study in Essential HypertensionNCT02194465 · 304 enrolled · United States, Canada, Puerto Rico
  12. Aug 20, 2014Phase 4 study in Erectile DysfunctionNCT02224846 · 635 enrolled · China
  13. Nov 20, 2014Phase 1 study in Healthy VolunteersNCT02300259 · 48 enrolled · United States
  14. Apr 28, 2015Phase 4 study in Prostatic HyperplasiaNCT02431754 · 171 enrolled · Japan

TargetBeta

PDE5A →read by rule
“Phosphodiesterase 5A inhibitor”ChEMBL 37, by rule

Other programs on PDE5A

ProgramCompanyFurthest phaseStudies
sildenafilruleViatrisphase 474

Studies

All 49 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02431754Prostatic Hyperplasia · Japan4CompletedFeb 2016171
NCT02300259Healthy Volunteers · United States1CompletedApr 201548
NCT02224846Erectile Dysfunction · China4CompletedMay 2016635
NCT02194465Essential Hypertension · United States, Canada, Puerto Rico2CompletedMar 2015304
NCT01937871Prostatic Hyperplasia · China3CompletedDec 2015909
NCT01865084Muscular Dystrophy, Duchenne · United States, Argentina, Belgium and more3TerminatedDec 2015331
NCT01824290Hypertension, Pulmonary · United States, Austria, Belgium and more3CompletedMar 18, 201935
NCT01484431Pulmonary Arterial Hypertension · United States, Canada, France and more2CompletedApr 21, 201720
NCT01460342Prostatic Hyperplasia · Japan, Korea, Republic of3CompletedOct 2012610
NCT01352507Erectile Dysfunction · China4CompletedJun 2012383
NCT01183650Prostatic Hyperplasia · Germany1CompletedApr 201124
NCT01160289Erectile Dysfunction · United States2CompletedNov 2011410
NCT01152190Prostatic Hyperplasia · United States, Austria, Italy3CompletedJul 201297
NCT01139762Prostatic Hyperplasia · United States, Argentina, Belgium and more3CompletedFeb 2012696
NCT01130532Erectile Dysfunction · United States, Canada4CompletedJan 2012623
NCT01122264Erectile Dysfunction · France, Germany, Greece and more4CompletedJun 2011770
NCT01026818Erectile Dysfunction · Belgium, Canada, France and more4CompletedOct 2012583
NCT00970632Prostatic Hyperplasia · Australia, Austria, Belgium and more3CompletedJan 2011511
NCT00861757Prostatic Hyperplasia · Japan, Taiwan3CompletedJun 2010612
NCT00855582Erectile Dysfunction · United States, Canada, France and more3CompletedJul 2010606
NCT00848081Prostatic Hyperplasia · United States, Puerto Rico3CompletedDec 2009318
NCT00836693Erectile Dysfunction · Germany, Greece, Italy and more3CompletedJan 2010217
NCT00833638Erectile Dysfunction · United States4CompletedJun 2009372
NCT00827242Prostatic Hyperplasia · United States, Argentina, Germany and more3CompletedNov 2009325
NCT00783094Prostatic Hyperplasia · Japan2CompletedJun 2009422
NCT00734604Erectile Dysfunction · United States, Australia, Brazil and more3CompletedSep 2009378
NCT00549302Hypertension, Pulmonary · United States, Belgium, Canada and more3CompletedFeb 2012357
NCT00547625Prostatic Hyperplasia · United States2Completed275
NCT00547599Erectile Dysfunction · Sweden4Completed659
NCT00547573Erectile Dysfunction · China3Completed367
NCT00547508Erectile Dysfunction · United States3Completed485
NCT00547495Erectile Dysfunction · Japan3Completed343
NCT00547417Erectile Dysfunction · United States3Completed1,933
NCT00547352Erectile Dysfunction · Korea, Republic of4Completed160
NCT00547287Erectile Dysfunction · Brazil3Completed2,760
NCT00547183Erectile Dysfunction · Germany3Completed298
NCT00547092Erectile Dysfunction · United Kingdom4Completed386
NCT00540124Prostatic Hyperplasia · Korea, Republic of2CompletedJun 2008151
NCT00422734Erectile Dysfunction · United States, Austria, France and more3CompletedJan 2008342
NCT00422578Erectile Dysfunction · Finland4Completed200
NCT00421083Erectile Dysfunction · United States3Completed180
NCT00386009Prostatic Hyperplasia · United States, Greece, Portugal2CompletedMay 2008200
NCT00384930Prostatic Hyperplasia · United States3CompletedOct 20071,058
NCT00382135Erectile Dysfunction · United States4Completed282
NCT00381732Erectile Dysfunction · United States3Completed280
NCT00333281Erectile Dysfunction · United States4Completed198
NCT00157326Hypertension · United States2Completed180
NCT00125918Hypertension, Pulmonary · United States, France, Italy3CompletedAug 2007406
NCT00050609Gastroparesis · Canada2Completed2

How it is read

Names in the registry

  • “tadalafil”, 45 entries
  • “Tadalafil”, 25 entries
  • “Tadalafil 20 mg”, 2 entries
  • “Cialis Tab. 5mg”, 2 entries
  • “Tadalafil 5 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.